Please use this identifier to cite or link to this item:
|Title:||SAFETY AND EFFICACY OF BOLUS ADMINISTRATION OF MAGNESIUM SULPHATE FOR PREECLAMPSIA|
Aziken, Michael Emefiele
|Publisher:||Trop J Obstet Gynaecol|
|Abstract:||Context: Magnesium sulphate is currently the drug of choice in the prevention and treatment of eclampsia. On-going research is addressing its administration in terms of dosage, duration and safety. Objective: We evaluated a modified method of magnesium sulphate administration with respect to safety, efficacy and maternofetal outcome. Design, Setting And Subjects: This was a prospective cohort study conducted at the UBTH, Benin City with patients managed for severe preeclampsia between June and December, 2011. The Zuspan regimen was compared with a modified intravenous regimen in which magnesium maintenance therapy was given as 1g hourly bolus injection administered over 10 minutes. Both methods were evaluated for safety, efficacy and materno-fetal outcome. Result: The mean age, parity, gestational age and body mass index were 28.09±5.5 years, 2.72±1.98, 36.67±3.54 weeks and 26.51±5.60 respectively. Both methods achieved therapeutic levels, but blood pressure control was better in the continuous group than the bolus group (27% vs 100%, P=0.000). Birth asphyxia occurred in 14.8% of the babies and was 3 times more in the continuous group (22% vs 7.5%; p=0.062). More babies in the bolus group were admitted to SCBU (54.1% vs 7.9%; p=0.000). There was no early neonatal death, and no maternal death in the first week of puerperium. Conclusion: This study showed that hourly bolus intravenous administration of magnesium sulphate is comparable to continuous intravenous therapy in terms of safety and efficacy in the treatment of severe preeclampsia. A larger scale study is recommended to further confirm our findings. Keywords: safety, efficacy, bolus magnesium sulphate, preeclampsia, University of Benin Teaching Hospital.|
|Appears in Collections:||Abstracts|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.